Trial Profile
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Genta (CEASED)
- 23 Jul 2018 New trial record